Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Robert I HaddadKevin J HarringtonMakato TaharaMatthew J FerrisMaura GillisonJerome FayetteAmaury DastePiotr KoralewskiBogdan ZurawskiMiren TabernaNabil F SabaMilena Perez MakAndrzej KaweckiGustavo C GirottoMiguel Angel Alvarez AvitiaCaroline EvenJoaquin Gabriel Reinoso ToledoAlexander D GuminskiUrs D A Müller-RichterNaomi KiyotaMustimbo RobertsTariq Aziz KhanKaren Miller-MoslinLi WeiAthanassios ArgirisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
CheckMate 651 did not meet its primary end points of OS in the all randomly assigned or CPS ≥ 20 populations. Nivolumab plus ipilimumab showed a favorable safety profile compared with EXTREME. There continues to be a need for new therapies in patients with R/M SCCHN.